The platelet adhesion cascade takes place in the presence of shear flow, a factor not accounted for in conventional (static) well-plate assays. This article reports on a platelet-aggregation assay utilizing a microfluidic well-plate format to emulate physiological shear flow conditions.
Part 1: Preparation of the microfluidic channels of a BioFlux plate.
Part 2. Preparing the blood with GPIIb/IIIa inhibitory antibody.
Part 3: Running the flow cell experiment on the BF1000 workstation.
Part 4: Representative Results.
Here the protocol for platelet adhesion and aggregation in microfluidic channels was presented. Treatment with a platelet aggregation inhibitor, anti-GPIIb/IIIa was also included in the protocol. Using collagen coated microfluidic channels of the BioFlux system, one should expect to see aggressive thrombus formation over time with the untreated control blood sample and no thrombus formation on the uncoated channel. In one recently performed experiment, the average size of aggregates under control conditions was 2000μm2.
Figure 1.
Activated GPIIb/IIIa is potent mediator of platelet-platelet interactions and aggregation stabilization1. Adhesion to collagen activates the GPIIb/IIIa complex to elicit this response 2. After incubation with anti-GPIIb/IIIa for 1 hour prior to shear exposure, one should expect to observe a decrease in size of thrombi as well as a decrease in the frequency of thrombus formation. A dose dependent response can typically be observed at 10dyn/cm2.
Figure 2.
The IC50 value for this particular inhibitor was 17nM at 10 dyn/cm2. Maximum inhibition (for this donor) compared to the no antibody control was 11% at 10 dyn/cm2.
While the methods here were presented using a specific extracellular matrix protein and a specific inhibitor of platelet aggregation, the protocol is extensible to other coatings, other cell types and other inhibitors for cell adhesion assays. The key ingredients to success of such experiments are avoidance of bubbles in the microfluidic channels, correct dilution of all reagents in the correct diluents, and appropriate incubation conditions for all reagents.
While the methods here were presented using a specific extracellular matrix protein and a specific inhibitor of platelet aggregation, the protocol is extensible to other coatings, other cell types and other inhibitors for cell adhesion assays. The key ingredients to success of such experiments are avoidance of bubbles in the microfluidic channels, correct dilution of all reagents in the correct diluents, and appropriate incubation conditions for all reagents.
The authors have nothing to disclose.
Material Name | Typ | Company | Catalogue Number | Comment |
---|---|---|---|---|
collagen I, Bovine | Reagent | Invitrogen | A1064401 | other sources of collagen I can be used |
PBS plus Ca/Mg | Reagent | Invitrogen | 14040-117 | |
Bovine serum albumin (BSA) | Reagent | EMD | EM-2930 Bottom of Form | From VWR |
calcein AM | Reagent | Invitrogen | C1430 | Calcein AM from BD can also be used |
BioFlux 1000 System | Reagent | Fluxion Biosciences | Contact Company | |
BioFlux Plate | Reagent | Fluxion Biosciences | 900013 | |
antiGPIIb/IIIa | Reagent | Abcam | ab33407 | an alternative # is ab15021 |
ReoPro | Reagent | Eli Lilly | by Rx only |